irinotecan has been researched along with lomeguatrib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Middleton, MR; Sabharwal, A | 1 |
| Brady, J; Corrie, PG; Margison, GP; Middleton, MR; Midgley, RS; Mortimer, P; Palmer, C; Sabharwal, A; Watson, AJ | 1 |
1 review(s) available for irinotecan and lomeguatrib
| Article | Year |
|---|---|
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
1 trial(s) available for irinotecan and lomeguatrib
| Article | Year |
|---|---|
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Purines; Treatment Outcome | 2010 |